Blog
In vivo CAR-T Insights Series (2) — Delivery Strategies Landscape
Release Time：
2025-12-03 15:53
One of the most critical challenges in developing in vivo CAR-T therapies lies in how we deliver genetic material to T cells safely and effectively inside the body. Broadly, two major delivery strategies are being explored:
🔹 Viral vectors (LV, AAV)
- High transduction efficiency
- But limited controllability and potential safety concerns
🔹 Non-viral vectors (LNPs, polymers)
- Improved safety and tunable properties
- Emerging as a promising alternative to viral methods
Among non-viral approaches, antibody–lipid nanoparticles (Ab-LNPs) stand out. By enabling cell-specific targeting, they hold the potential to overcome delivery bottlenecks and pave the way for more precise in vivo CAR-T generation.
Levostar’s in vivo CAR-T solutions
From mRNA plasmid design to LNP formulation, Levostar provides complete solutions for in vivo CAR-T research.
Our Ab-LNP technology enables targeted delivery — from ready-to-use standard products (e.g., LNP-CD3/5/8) to fully customized antibody conjugation services.
👉 Stay tuned — in the upcoming posts, we will dive deeper into Ab-LNPs and their unique advantages in targeted T cell engineering.
Let’s accelerate the future of cell therapy — directly inside the body.
E-mail：support@levostar.com
USA
16192 Coastal Hwy，Lewes, DE 19958
TEL：619-537-9202
China
A3-502 No.328, Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu, China 215123
TEL：0512-62888898